Search

Glaukos Corp

Fermé

SecteurSoins de santé

182.91 3.09

Résumé

Variation du prix de l'action

24h

Actuel

Min

178.36

Max

185.6

Chiffres clés

By Trading Economics

Revenu

1.4M

-18M

Ventes

35M

186M

BPA

-0.14

Marge bénéficiaire

-9.901

Employés

1,094

EBITDA

-333K

-5.6M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+10.83% upside

Dividendes

By Acuity

Prochains Résultats

28 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.6B

11B

Ouverture précédente

179.82

Clôture précédente

182.91

Glaukos Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 oct. 2026, 20:01 UTC

Glaukos Corporation shares are experiencing higher trading activity today, reaching a notable peak earlier in the session before pulling back slightly.

26 oct. 2026, 23:46 UTC

Glaukos Corp shares are trading higher in after-market hours, remaining near the upper end of their one-month trading range.

22 oct. 2026, 20:07 UTC

Glaukos Corp shares are declining, retracing from an early session peak to approach the day's low amid a slight overall market decline.

21 oct. 2026, 20:07 UTC

Glaukos Corp shares advanced throughout Wednesday, peaking in the afternoon before a slight pullback, remaining above their 20-day moving average.

20 oct. 2026, 20:01 UTC

Glaukos Corp shares are significantly higher, currently 7.32% above their 20-day moving average and near the upper end of their one-month range.

16 oct. 2026, 19:36 UTC

Glaukos Corp shares fell sharply, marking a notable decline since Thursday's close and currently positioned around the midpoint of its one-month trading range.

15 oct. 2026, 20:07 UTC

Glaukos Corp shares are declining, reversing an early spike to finish lower from Wednesday's close amid unusual volatility.

13 oct. 2026, 20:07 UTC

Glaukos Corp shares are declining, following a volatile intraday pattern, closing lower from Monday's close despite briefly recovering earlier in the session.

9 oct. 2026, 20:06 UTC

News
Event

Glaukos reports positive Phase 4 trial results for iDose TR therapy, showing a significant reduction in intraocular pressure alongside cataract surgery, confirming safety.

8 oct. 2026, 22:55 UTC

Glaukos Corp shares declined in after-market hours, continuing a downward trend from Thursday's close and remaining below its 20-day moving average.

7 oct. 2026, 20:00 UTC

Glaukos Corp is advancing significantly with unusually high trading volume, marking a departure from recent higher daily closes since Tuesday.

6 oct. 2026, 20:07 UTC

Glaukos Corp shares are declining, trading below their 20-day moving average and near the lower end of their one-month range after earlier volatility.

1 oct. 2026, 20:07 UTC

Glaukos Corp's shares are declining, positioned near the lower end of their one-month range, after a brief spike earlier in the session.

30 sept. 2026, 20:07 UTC

Glaukos Corp shares are advancing, rebounding from an earlier pullback, amid a broader market trend of significant gains on Wednesday.

29 sept. 2026, 23:55 UTC

Glaukos Corp is trading modestly higher in after-market hours, despite fluctuations during the session, and remains below its 20-day moving average.

28 sept. 2026, 20:07 UTC

Glaukos Corp is gaining ground in today's trading session, reflecting upward momentum since Friday, despite earlier pulling back from a session high.

25 sept. 2026, 20:07 UTC

Glaukos Corp shares fell sharply, closing just below Thursday's close and approximately 9.45% below their 20-day moving average.

23 sept. 2026, 20:01 UTC

News

Glaukos Corporation launched a keratoconus awareness campaign with Stephen Curry, but shares fell sharply today, continuing a trend of three consecutive daily declines.

22 sept. 2026, 23:01 UTC

Glaukos Corp is advancing in after-market trading, reflecting a directional move since Tuesday's close, though it remains 6.99% below its 20-day moving average.

21 sept. 2026, 20:06 UTC

Glaukos Corp's shares are declining, remaining below their 20-day moving average and near the lower end of their one-month range despite an earlier session recovery.

18 sept. 2026, 20:02 UTC

Glaukos Corp is advancing during market hours on Friday, continuing its upward trend since Thursday's close, despite lower trading compared to earlier sessions.

17 sept. 2026, 19:36 UTC

Glaukos Corp shares fell sharply, currently at their lowest point of the day and significantly below the 20-day moving average.

16 sept. 2026, 19:03 UTC

Glaukos Corp shares fell sharply, reversing a trend of higher daily closes, amid unusually high market volume on Wednesday.

14 sept. 2026, 19:16 UTC

Glaukos Corp shares are higher today, despite no specific news, following three consecutive sessions of declines. The stock remains below its 20-day moving average.

11 sept. 2026, 20:08 UTC

Glaukos Corp shares are lower today, continuing a decline over the past four sessions and trading below the 20-day moving average.

10 sept. 2026, 20:03 UTC

Glaukos Corp shares are lower today, breaking a trend of higher closes. The stock is trading with unusually high volume amid no specific news.

8 sept. 2026, 20:07 UTC

Glaukos Corp shares are higher today, recovering from an early dip amid speculation of a potential interest rate hike following a strong jobs report.

1 sept. 2026, 19:31 UTC

Glaukos Corp. shares are lower today amid broader market volatility and rising U.S. Treasury yields, continuing a three-session decline.

31 août 2026, 20:07 UTC

Glaukos Corp shares are lower amid broader market concerns over inflation and potential Fed rate hikes. Earlier, the stock rebounded from a session low.

28 août 2026, 20:07 UTC

Glaukos Corp shares are lower during Friday's session amid rising U.S. Treasury yields and broader market trends, with no specific company news identified.

Comparaison

Variation de prix

Glaukos Corp prévision

Objectif de Prix

By TipRanks

10.83% hausse

Prévisions sur 12 Mois

Moyen 197.583 USD  10.83%

Haut 225 USD

Bas 172 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

12

Achat

1

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat